Table 1 Baseline characteristics of safety and per protocol patients per up-dosing regimen
Safety population | Per protocol | |||||||
|---|---|---|---|---|---|---|---|---|
Regular | Intermediate | Fast | Overall | Regular | Intermediate | Fast | Overall | |
Patients (n) | 6 | 21 | 21 | 48 | 5 | 19 | 15 | 39 |
Mean age ± SD (yrs) | 27.5 ± 4.9 | 32.1 ± 11.4 | 31.2 ± 10.6 | 31.2 ± 10.4 | 27.2 ± 5.5 | 31.8 ± 11.3 | 33.1 ± 10.4 | 31.7 ± 10.3 |
BMI ± SD (kg/m2) | 27.5 ± 5.9 | 24.4 ± 3.5 | 26.7 ± 6.2 | 25.8 ± 5.2 | 27.7 ± 6.6 | 24.5 ± 3.4 | 26.7 ± 5.9 | 25.8 ± 4.9 |
Patients with other allergies n (%) | 5 (83.3%) | 12 (57.1%) | 12 (57.1%) | 29 (60.4%) | 4 (80%) | 10 (52.6%) | 9 (60.0%) | 23 (59.0%) |
SPT HDM D. pter ± SD (mm) | 6.5 ± 3.1 | 6.6 ± 2.7 | 7.4 ± 4.5 | 6.9 ± 3.6 | 7.0 ± 3.2 | 6.6 ± 2.8 | 8.0 ± 5.2 | 7.2 ± 3.9 |
SPT HDM D. far ± SD (mm) | 7.8 ± 2.6 | 7.1 ± 1.9 | 7.0 ± 3.9 | 7.1 ± 3.0 | 8.2 ± 2.8 | 7.0 ± 1.9 | 7.2 ± 4.4 | 7.2 ± 3.2 |
ssIgE ± SD (U/ml) | 16.0 ± 19.7 | 23.4 ± 23.8 | 26.2 ± 28.2 | 23.7 ± 25.1 | 17.1 ± 21.8 | 24.5 ± 24.7 | 34.1 ± 29.9 | 27.3 ± 26.5 |